Avalon GloboCare Provides Second Quarter 2018 Business Update; Reports 32% Increase in Revenues
FREEHOLD, N.J., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, today announced financial results and provided a business update for the second quarter ended June 30, 2018.
Second Quarter 2018 Highlights:
- Revenues increased 32% to $496,093 for the second quarter ended June 30, 2018;
- Cash at June 30, 2018 was $3.6 million;
- Formed joint laboratory with top-ranked hospital in Shanghai for regenerative exosomics;
- Appointed Former Deputy Secretary of the U.S. Department of Health and Human Services Dr. Tevi Troy to Board of Directors;
- Formed joint venture with Jiangsu Unicorn to establish provincial network of translational cellular therapy and bio-banking programs;
- Appointed Senior Healthcare Executive William Stilley to Board of Directors
David Jin, M.D., Ph.D., CEO and President of Avalon GloboCare Corp., commented, “We continue to make rapid progress towards the advancement of our cell-based therapies and exosome technology platform. Notably, we have formed a strategic partnership with the Shanghai Ninth People’s Hospital, a top-ranked medical institute in China and the Asia Pacific region, renowned for its plastic and reconstructive surgery specialty. This strategic partnership with the Shanghai Ninth People's Hospital is the first of its kind in establishing an innovative, state-of-the-art joint laboratory in regenerative exosomics. The joint laboratory will utilize Avalon’s proprietary exosome isolation system to in order to accelerate the development of diagnostic and therapeutic applications particularly in the areas of plastic/reconstructive surgery, wound healing, skincare, and exosomic bioinformatics. In addition, we have formed a joint venture with Jiangsu Unicorn Biological Technology Co. Ltd to establish provincial network of translational cellular therapy and bio-banking programs. A major initiative of this joint venture is to establish the world’s largest aqueous humor derived exosome bio-bank to advance the next-generation of diagnosis and therapeutics for ophthalmologic diseases. Through this provincial network of translational programs, we are able to further strengthen our leadership role and capabilities in order to accelerate our growth and development in regenerative medicine and cellular therapies.”
“Throughout the second quarter of 2018, we continued to move forward towards a NASDAQ uplisting by appointing prominent independent board members, Dr. Tevi Troy and William Stilley. Dr. Tevi Troy brings extensive government relationships and experience in the healthcare industry that will aid in accelerating the development of our cell-based therapies and exosome technology platform. William Stilley is the perfect fit to chair our audit committee as he brings valuable operational, financial and strategic experience, including product licensing, partnering, financing, and M&A. We are also pleased to announce that we completed a $2.1 million financing with strategic investors in August 2018, which further strengthens our balance sheet and shareholders’ equity in advance of a listing on a national exchange.” concluded Dr. Jin.
Revenues for the second quarter ended June 30, 2018 were $496,093 versus $374,751 for the second quarter ended June 30, 2017. The increase in revenues was due to property rental income, development services and sales of developed products. Operating loss for the quarter ended June 30, 2018 was $1.2 million versus operating loss of $0.4 million for second quarter ended June 30, 2017, which reflects increased SG&A expenses to support the anticipated growth, as well as an increase in public company expenses in advance of the planned listing on a national exchange. Net loss attributable to Avalon GloboCare Corp. common shareholders for the second quarter ended June 30, 2018 was $1.3 million or ($0.02) earnings per share, versus net loss attributable to Avalon GloboCare Corp. common shareholders of $0.4 million or ($0.01) earnings per share for the second quarter ended June 30, 2017.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (OTCQB:AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high impact, transformative cell-based /technologies and their clinical applications, as well as healthcare facility management through its core platforms, namely "Avalon Cell" and "Avalon Rehab." In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance their clients' growth, development, as well as competitiveness in both domestic and global healthcare markets. Avalon also engages in the management of stem cell banks and specialty clinical laboratories. Through its U.S. subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon will further establish our leading roles in the fields of CAR-T therapy, liquid biopsy, precision medicine and regenerative medicine.
Forward-Looking Statements
Certain statements contained in this press release may constitute "forward-looking statements." Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020
avco@crescendo-ir.com
(tables follow)
AVALON GLOBOCARE CORP. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
| As of | ||||||||
| June 30, 2018 | December 31, 2017 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| CURRENT ASSETS: | ||||||||
| Cash | $ | 3,643,316 | $ | 3,027,033 | ||||
| Accounts receivable, net of allowance for doubtful accounts | 74,969 | 10,179 | ||||||
| Accounts receivable - related party, net of allowance for doubtful accounts | 144,779 | — | ||||||
| Tenants receivable, net of allowance for doubtful accounts | 38,527 | 38,469 | ||||||
| Security deposit | 328,615 | 6,916 | ||||||
| Inventory | 22,049 | 2,667 | ||||||
| Prepaid expenses and other current assets | 707,925 | 149,713 | ||||||
| Total Current Assets | 4,960,180 | 3,234,977 | ||||||
| OTHER ASSETS: | ||||||||
| Security deposit - noncurrent portion | — | 25,322 | ||||||
| Prepayment for long-term assets | 67,044 | 153,688 | ||||||
| Property and equipment, net | 143,226 | 48,029 | ||||||
| Investment in real estate, net | 7,725,301 | 7,623,757 | ||||||
| Intangible assets, net | 1,419,474 | 1,583,260 | ||||||
| Total Other Assets | 9,355,045 | 9,434,056 | ||||||
| Total Assets | $ | 14,315,225 | $ | 12,669,033 | ||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Accounts payable | $ | 1,702 | $ | 29 | ||||
| Accrued liabilities and other payables | 299,788 | 124,064 | ||||||
| Accrued liabilities and other payables - related parties | 48,694 | 39,927 | ||||||
| Deferred rental income | 11,182 | 12,769 | ||||||
| Loan payable | 1,000,000 | 1,500,000 | ||||||
| Interest payable | 24,931 | 138,110 | ||||||
| VAT and other taxes payable | 12,516 | 2,997 | ||||||
| Tenants’ security deposit | 73,400 | 92,288 | ||||||
| Due to related party | 450,000 | 450,000 | ||||||
| Refundable deposit | 2,000,000 | 3,000,000 | ||||||
| Total Current Liabilities | 3,922,213 | 5,360,184 | ||||||
| Commitments and Contingencies - (Note 20) | — | — | ||||||
| EQUITY: | ||||||||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; | ||||||||
| no shares issued and outstanding at June 30, 2018 and December 31, 2017 | — | — | ||||||
| Common stock, $0.0001 par value; 490,000,000 shares authorized; | ||||||||
| 73,560,622 shares issued and 73,040,622 shares outstanding at June 30, 2018; | ||||||||
| 70,278,622 shares issued and outstanding at December 31, 2017 | 7,356 | 7,028 | ||||||
| Additional paid-in capital | 18,034,773 | 11,490,285 | ||||||
| Less: common stock held in treasury, at cost; | ||||||||
| 520,000 and 0 shares at June 30, 2018 and December 31, 2017, respectively | (522,500 | ) | — | |||||
| Accumulated deficit | (6,293,627 | ) | (3,517,654 | ) | ||||
| Statutory reserve | 6,578 | 6,578 | ||||||
| Accumulated other comprehensive loss - foreign currency translation adjustment | (135,404 | ) | (91,994 | ) | ||||
| Total Avalon GloboCare Corp. stockholders’ equity | 11,097,176 | 7,894,243 | ||||||
| Non-controlling interest | (704,164 | ) | (585,394 | ) | ||||
| Total Equity | 10,393,012 | 7,308,849 | ||||||
| Total Liabilities and Equity | $ | 14,315,225 | $ | 12,669,033 | ||||
AVALON GLOBOCARE CORP. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| For the Three Months Ended | For the Three Months Ended | For the Six Months Ended | For the Six Months Ended | |||||||||||||
| June 30, 2018 | June 30, 2017 | June 30, 2018 | June 30, 2017 | |||||||||||||
| REVENUES | ||||||||||||||||
| Real property rental | $ | 278,872 | $ | 222,254 |
By: Nasdaq / GlobeNewswire
- 15 Aug 2018
Back to overview
Enhance your business development with Biotechgate
| |||||||||||